<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
TARRYTOWN, N.Y., Aug. 5, 2021 /PRNewswire/ — Second quarter 2021 revenues increased 163% to $5.14 billion versus second quarter 2020 including $2.76 billion attributable to REGEN-COV TM(2) ; revenues excluding REGEN-COV (1)(2) increased 22% Second quarter 2021 EYLEA® U.S. net sales increased 28% versus second quarter 2020 to a record $1.42 billion Second quarter 2021 Dupixent® global net sales (3) , which are recorded by Sanofi, increased 59% to $1.50 billion versus second quarter 2020 Second quarter 2021 GAAP diluted EPS was $27.97 and non-GAAP diluted EPS (1) was $25.80 FDA updated REGEN-COV Emergency Use Authorization (EUA) with lower dose, subcutaneous administration, and post-exposure prophylaxis REGEN-COV Phase 3 RECOVERY trial in hospitalized patients with severe COVID-19 met primary outcome Reported that Dupixent significantly improved itch and hives in patients with chronic spontaneous urticaria, marking the fifth disease to show positive pivotal results Phase 3 trial of Libtayo® combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the second quarter of 2021 and provided a business update.
...read full article on PRNewsWire
